Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Patients are often diagnosed with advanced stage EOC which has a high chance of cancer recurrence and metastasis and thus with a poor survival rate. It remains a huge challenge to understand the cellular and molecular mechanisms of the aggressive behaviour of EOC cells. In this study we investigated the role of an immunomodulatory cytokine IL-33 and its receptor ST2 in mediating the growth and metastasis of EOC, and the association of their expression with disease prognosis.
Introduction
Ovarian cancers are a group of heterogeneous, rapidly progressing gynaecological malignancies with high rate of mortality in women. Epithelial ovarian cancer (EOC) is the most lethal ovarian cancer accounting for 80 to 90% of all cases, with serous ovarian carcinoma as the most common and most aggressive subtype of EOC (Bell, 2005; Kurian et al., 2005; Marquez et al., 2005) . Despite recent advances in surgical resections and systemic chemotherapies, the prognosis of EOC remains poor and the 5-year survival rate is only approximately 30% after initial diagnosis (Armstrong, 2002; Jemal et al., 2009; McGuire et al., 1996) . The main reason for the poor survival rate is that currently there are no effective screening methods for early symptoms of EOC which are often silent. 70% of patients are first diagnosed with advanced stage of the disease with metastasis, which remains the leading cause of cancer relapse and ultimately death from EOC (Goff et al., 2000; Heintz et al., 2006; Stirling et al., 2005) . Thus there is an urgent need to investigate the molecular mechanisms associated with the aggressive growth and metastatic ability of ovarian cancer.
IL-33 is a member of the IL-1 cytokine family, originally described as a nuclear protein in high endothelial venules (Baekkevold et al., 2003) . IL-33 is expressed in many organs and cells (Schimitz et al., 2005) , it induces synthesis of various chemokines and cytokines such as IL-5 and IL-13 via binding to its heterodimeric receptor ST2
and IL-1R accessory protein (Liew, 2012) . ST2 exists in two forms due to the alternative splicing: a transmembrane full-length form (ST2L) and a soluble, secreted form (sST2) acting as a decoy receptor (Oshikawa et al., 2002) . ST2 is expressed by various immune cells including dendritic cells (DCs), Th2 cells, mast cells and natural killer (NK) cells (Lohning et al., 1998; Moritz et al., 1998; Xu et al., 1998) , as well as tissue specific cells such as endothelial cells and decidual stromal cells (Hu et al., 6 2014; Zeyda et al., 2013) .
Since the discovery of IL-33 in 2005 (Schmitz et al., 2005) , numerous studies have suggested that IL-33 plays diverse but important roles in immune mediated diseases such as infection, allergy and autoimmune diseases (Liew, 2012) . Interestingly, a few recent studies in cancer indicate a potential role of IL-33 in modulating anti-tumour immunity and tumour growth. Elevated levels of IL-33 have been detected in the serum samples of gastric cancer (Sun et al., 2011) , non-small cell lung cancer (Hu et al., 2013) and breast cancer patients , while the serum levels of sST2
were reported to be associated with worse prognostic factors in hepatocellular (Bergis et al., 2013) and breast cancer (Lu et al., 2014) , suggesting IL-33/ST2
signaling pathway is likely to be involved in the development of a variety of cancers.
However, the function of IL-33 in tumour progression is less clear. While transgenic expression of IL-33 in mice activated NK and CD8 T cells and inhibited tumour growth and metastasis in melanoma and lung carcinoma animal models (Gao k., et al., 2013; Gao X., et al., 2015) , induced IL-33 expression enhanced the tumourigenic activity of rat glioma cells (Fang et al., 2014) . In addition, the IL-33/ST2 axis promoted mouse mammary carcinoma growth and metastases by facilitating intratumoural accumulation of immunosuppressive cells (Jovanovic et al., 2011 and . Thus despite convincing evidence suggesting a role for IL-33/ST2 in cancer growth and progression, its exact function and more importantly the underlying mechanisms in tumour development remain unclear.
In this study we focused on the role of IL-33/ST2 in the development of EOC and examined the underlying mechanism of its function. We evaluated the correlation of the expression levels of IL-33 and ST2 in dissected tumour tissues with the survival 0h and 48h. The area of the wound in each well was calculated using Image software.
Transwell invasion assay
EOC cell invasion was evaluated using a matrigel invasion chamber. Briefly, the cell inserts (Corning) were coated with 100l of matrigel (BD BioScience) and then placed in a 24-well plate. Cells (4×10 5 /ml) suspended in 100l of medium containing 0.1% FBS with/without rhIL-33, sST2, U0126 or SP600125 were seeded in the top chambers. Dimethylsulfoxide (DMSO) was used to dissolve U0126 and SP600125 in our experiments, the final concentration of DMSO in the cell culture was 0.05% (v/v).
The lower chambers were filled with 600l of medium containing 10% FBS. After 48h incubation, the inserts were removed and washed in PBS before being fixed and stained with hematoxylin. The non-invading cells together with the matrigel were removed and the cells migrating to the lower surfaces were examined and counted at a magnification of ×200 in five predetermined fields. Each experiment was carried out in triplicate. 
Immunohistochemistry
Formalin-fixed, paraffin-embedded EOC tissue sections (5m) were dewaxed and rehydrated before an antigen retrieval step. Sections were then incubated with anti-human primary antibodies for IL-33 (Enzo Life Sciences), ST2 (Sigma-Aldrich),
Ki-67 (Abcam) or matching IgG isotypes overnight. Slides were then stained with species specific biotinylated secondary antibodies (R&D Corporation), streptavidin-HRP and detected with substrate AEC (3-amino-9-ethylcarbazole) (Vector Laboratories). After that, slides were counterstained with hematoxylin. The staining intensity was scored independently by two pathologists with strong staining marked as 2+, weak staining marked as 1+ and minimal staining as 0 [29, 30] . Three sections from each sample were examined.
For EOC cell lines, cells were cultured on glass coverslips coated with poly-D-lysine (Sigma) with or without rhIL-33 in the culture medium for 48h. Cells were then fixed and incubated with anti-Ki-67 and other primary antibodies, and the subsequent staining steps were performed as described above.
Protein extraction and western blot
Total protein was harvested from cells and tissues, and protein concentrations were determined using Quick Start Bradford protein assay (Bio-Rad). Aliquots of samples were separated by SDS-PAGE and transferred to nitrocellulose membrane.
Membranes were incubated with primary antibodies at 4 ºC overnight. Protein bands were detected by incubation with HRP-conjugated antibody (Pierce Biotechnology, USA) and visualized with Clarity Western ECL Substrate (Bio-Rad). Following antibodies used in the study were purchased from Cell Signaling Technology (Danvers, USA): β-actin, NF-B, phospho-NF-B p65 (Ser536), p38, phospho-p38
p44/42MAPK/ERK, and phospho-p44/42MAPK/ERK (Thr202/Tyr204).
Statistical analysis
Results are expressed as mean+SEM and the data are representative of at least three separate experiments. The Wilcoxon-Mann-Whitney test was used to determine the statistical differences of cell proliferation, migration and invasion between two samples. The comparison between protein expression levels in different groups (Fig 1C and Tables 1 and 2) was assessed using Fisher's exact test. Overall survival curves were generated using Kaplan-Meier method and compared using a log-rank test. P value <0.05 was regarded as statistically significant. 
Results

The expression levels of IL-33 and ST2 are associated with metastasis and proliferation of EOC
We first examined whether IL-33 and ST2 were expressed by normal ovary and ovarian tumour tissues using immunohistochemical staining, and the expression levels were then analyzed according to the established criteria for high-expression (staining 2+）and low-expression (staining 0 or 1+) (Gonzalez-Campora et al., 2011) .
Our data showed that IL-33 was undetectable in normal ovary tissues, and the expression levels were highly up-regulated in EOC samples with IL-33 positive staining localized to the cytoplasm as well as on the cell nucleus ( Fig 1A) . Similar to IL-33 expression, ST2 was not expressed by normal ovary tissues while high levels of ST2 positive staining were observed in EOC tissues with ST2 localized to the membrane and cytoplasm of cells (Fig 1B) . Interestingly, when we compared the expression levels of IL-33 and ST2 in the tumours collected from the primary and metastatic sites, stronger staining of both IL-33 and ST2 was observed by the metastatic tumours, with additional nuclear staining of ST2 in the metastatic tumour cells but not primary tumour cells (Fig 1A and 1B) .
To understand whether there is a correlation between the expression levels of IL-33 and ST2 and EOC metastasis, we screened the paraffin-embedded tissues of 20 normal ovary, 20 benign tumours and 114 EOC samples. Our results (Table 1) show that all normal ovary tissues had low expression of IL-33 or ST2, with 10%-20% of ovary benign tumours had high expression levels of the molecules. However in EOC samples, there was a significant upregulation of IL-33 expression with 59% of primary site and 76% of metastatic EOC tumours had high levels of expression. The statistical 14 difference was more significant for ST2 expression as 87% of metastatic tumours had high ST2 expression compared to 66% of primary site tumours. Furthermore there was a significant correlation between the expression levels of IL-33 and ST2 in EOC and tumour metastasis. Using western blotting, we further assessed the difference of IL-33 and ST2 expression in paired primary site and metastatic site EOC tumours.
Samples were collected at operative resection with each case being confirmed by pathology examination. Our data show (Fig 1C) that out of twelve patients, eight had increased expression of IL-33 in metastatic tumours compared with the primary tumours while nine out of twelve metastatic tumours had increased ST2 expression, the differences were statistically significant for both IL-33 and ST2 using Fisher's test.
Taken together our findings from both western blotting and immunohistochemical staining suggest that high levels of IL-33 and ST2 expression were closely correlated with EOC metastasis.
The up-regulation of IL-33 and ST2 in EOC is an indicator of tumour cell proliferation and poor prognosis
In addition to the tumour metastasis, we further analyzed whether there was a correlation between the expression levels of IL-33 and ST2 and patient age and other clinic pathological characteristics of EOC. Surprisingly, our data suggested that there was no significant correlation between the expression levels of IL-33 or ST2 and patient age, tumour histologic types, FIGO stages or differentiation (Table 2) .
However, IL-33 and ST2 expression levels were positively correlated with the expression of Ki-67 (Fig 2A, Table 2 ), further confirming a potential role of IL-33/ST2
signaling axis in EOC growth and metastasis. To understand the clinical implications of the up-regulation of IL-33 and ST2, we collected and analyzed the clinical follow up 15 data of EOC patients. Our Kaplan-Meier patient overall survival analysis curves
showed that higher expression level of IL-33 was closely correlated with reduced survival time for EOC patients (Fig 2B) , and the correlation was even more significant with the expression level of ST2 (Fig 2C) . Thus the data here show that IL-33/ST2
axis plays an important role in ovarian cancer progression and are poor prognostic markers for patients.
Knock down of IL-33 gene reduces the migratory and invasive potential of EOC cells
The close correlation of IL-33/ST2 expression with EOC progression, particularly tumour metastasis suggests that IL-33/ST2 may be important in ovarian cancer cell growth, migration and invasion. We studied the role of IL-33 in EOC cell behaviour using cell lines. First we examined the expression of IL-33 and ST2 by EOC cell lines CAOV3, HO8910 and SKOV3-DDP. In agreement with our staining data of EOC patient tumour tissues, both IL-33 and ST2 were highly expressed by all three cell lines as confirmed by both immunohistochecmial staining (data not shown) and western blot ( Fig 3A) . Next, we disrupted IL-33 gene expression in the cell lines using siRNA, and tested the effect of endogenous IL-33 on EOC cell function. After transfection of IL-33 specific siRNA, the expression of IL-33 was dramatically decreased in all three cell lines as expected (Fig 3B) when compared with scramble control cells. Furthermore, cell viability, migration and invasion assays were performed to evaluate the role of IL-33 in EOC cell behaviour. While IL-33 knock-down had no effect on cell viability/proliferation in all three cell lines (data not shown), the cells transfected with IL-33 siRNA had significantly reduced their migration ( Fig 4A) and invasion capacity (Fig 4B) as tested by the wound healing and transwell invasion assays. 
Fl-hIL-33 increases the migratory, invasive and proliferative potential of EOC cells
To understand the function of IL-33/ST2 in EOC development, we investigated the effect of exogenous IL-33 on cell metabolic activity, invasion and migration using CAOV3 and HO8910 cell lines. Cells were first incubated with or without 200ng/ml sST2 for 3h before adding 10ng/ml of fl-hIL-33 in the culture for a further 48h. As shown in Figure 4 , fl-hIL-33 not only increased the cell migration ( Fig 5A) and invasion ( Fig 5B) , but also enhanced the cell viability/proliferation of both cell lines ( Fig 5C) . Furthermore, the staining of Ki-67 protein was also elevated in the cells treated with fl-hIL-33 (Fig 5D) . While the administration of IL-33 decoy receptor sST2 was able to block the stimulatory effect of fl-hIL-33 on EOC cell migration, invasion and proliferation, sST2 also decreased IL-33-induced up-regulation of Ki-67 in EOC cells (Fig 5) .
Fl-hIL-33 increases ovarian cancer migration, invasion and proliferation through ERK and JNK pathways
Numerous signaling pathways are involved in the aggressive behaviour of cancer cells, unraveling these signaling networks will provide important insights into cancer development. To understand the molecular mechanisms of IL-33/ST2 effect on ovarian cell growth and metastasis, we next investigated the changes in the signaling pathways of EOC cells after treatment with fl-hIL-33. We observed an obvious increase in the phosphorylation of JNK and ERK with a peak of phosphorylation occurring at 10mins after fl-hIL-33 stimulation, but no change was observed with NF-B and p38 (Fig 6A) . Phosphorylation of ERK and JNK was completely blocked 17 by sST2 (Fig 6B) . We further demonstrated that U0126 (2µmol/l), an inhibitor of MAPK/ERK, significantly inhibited the phosphorylation of ERK in CAOV3 and HO8910 cells (Fig 7A) . It also blocked the IL-33 mediated increase of cell migratory ( Fig 7C) and invasive (Fig 7D) potential, together with cell viability/proliferation in CAOV3 cells (Fig 7E) . When the JNK pathway inhibitor SP600125 (10µmol/l) was added to the cells, it inhibited JNK phosphorylation in CAOV3 and HO8910 cells as expected (Fig 7B) . Surprisingly SP600125 had no effect on the IL-33-induced increase in cell migratory ( Fig 7C) and invasive ( Fig 7D) potential, and was only able to disrupt IL-33-induced enhancement of cell viability/proliferation (Fig 7E) of CAOV3 cells. DMSO was used to dissolve SP600125 and U0126 and our control experiments confirmed that low concentrations of DMSO used in the study had no effect on EOC cell behavior and the phosphorylation of JNK and ERK ( Supplementary Fig 1) .
Collectively, our data demonstrate that the different roles of IL-33/ST2 in ovarian cancer cell growth, migration and invasion are mediated by complex signaling pathways.
Discussion
New evidence suggests that IL-33/ST2 axis is likely to play a role in cancer development and progression (Milovanovic et al., 2012) , however its exact function in ovarian cancer growth and metastasis has not been defined. To our knowledge, our study is the first to demonstrate that the expression levels of both IL-33 and ST2 in EOC tumours are closely correlated with tumour metastasis and patient prognosis, and IL-33/ST2 axis contributes to EOC progression through mechanisms of promoting cancer cell growth and migration.
Several recent studies suggest that serum levels of IL-33 (Sun et al., 2011; Hu et al., 2013 ) and sST2 (Bergis et al., 2013; Lu et al., 2014) A few studies have examined the role of IL-33 in anti-tumour immune responses during cancer development (Gao et al., 2013; Jovanovic et al., 2011; Milovanovic et al., 2012) however with contradictory results. One study suggested that IL-33 acted as a crucial mediator in inflammation-associated pancreatic carcinogenesis by up-regulating secretion of the pro-inflammatory IL-6 and IL-8 cytokines (Schmieder et al., 2012) . Transgenic IL-33 was shown to be able to activate NK and CD8 T cells and inhibited tumour growth and metastasis in melanoma and lung carcinoma animal models (Gao K, et al., 2013; Gao X, et al., 2015) . Other reports showed that IL-33 20 enhanced type-2 immune responses (Barbour et al., 2014; Besnard et al., 2011; Kurowska-Stolarska et al., 2009; Jiang et al., 2012; Miller et al., 2008; ) influences the malignant potential of the tumour through the promotion of angiogenesis in the tumour microenvironment (Ishikawa et al., 2014) . In our immunohistochemical staining data, we observed that IL-33 and ST2 were highly expressed by cancer cells and also the surrounding stromal cells, suggesting there might be a close interaction between the EOC and stromal cells.
IL-33 binds to ST2 and activates the downstream signaling pathways through NF-B as well as MAPKs pathways (Liew, 2012) , key signaling pathways for cancer cell activities such as proliferation, migration and invasion. Current evidence indicates that gene-and cell-specific differences often exist in IL-33 activated signaling pathways (Milovanovic et al., 2012; Zhou et al., 2014) . NF-B is a key player in innate immunity and inflammation, and the IL-33 effect on cytokine production appeared to be mediated via NF-B activation as shown in pancreatic carcinoma cells (Schmieder et al., 2012) . Other studies show that P38 signaling pathway was associated with the pro-melanogenic activity of IL-33 in primary melonocytes , while IL-33 enhanced proliferation and invasiveness of decidual stromal cells were mediated via both NF-B and ERK1/2 signaling . (0, 10, 30, 60, 120mins) and then harvested for western blot assay of P-NF-B, NF-B, P-JNK, JNK, P-P38, P38, P-ERK1/2, ERK1/2 and β-actin.
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